Advanced Biomed Inc. Announces Definitive Agreement to Acquire Acellent Technologies (Hong Kong) Co. Limited

Key Highlights

• Acquisition Announcement: On April 2, 2026, Advanced Biomed Inc. (NASDAQ: ADVB) entered into a definitive Share Purchase Agreement to acquire 100% of the equity of Acellent Technologies (Hong Kong) Co. Limited.
• Purchase Price: The total consideration for the acquisition is 270,000 shares of Advanced Biomed’s common stock, valued at \$4.00 per share, amounting to an aggregate estimated value of \$1,080,000.
• Target’s Business: Acellent Technologies (Hong Kong) Co. Limited is a Hong Kong-incorporated company specializing in AI-powered financial verification and audit solutions.
• Closing Conditions: The transaction is subject to financial and legal due diligence, as well as receipt of all required regulatory approvals.
• Price Sensitivity: The acquisition involves the direct issuance of new shares and could impact Advanced Biomed’s share structure and value. The entry into the AI-powered financial services sector may positively influence investor sentiment and the company’s valuation.
• Emerging Growth Company: Advanced Biomed Inc. remains classified as an emerging growth company under relevant SEC rules, and has not elected to adopt the extended transition period for new or revised accounting standards.

Details of the Transaction

Under the terms of the Share Purchase Agreement, Advanced Biomed Inc. (“the Company”) will acquire all outstanding shares of Acellent Technologies (Hong Kong) Co. Limited (“the Target”) from its sole shareholder. The consideration consists of 270,000 shares of the Company’s common stock, with each share valued at approximately \$4.00, leading to a total transaction value of \$1,080,000.

The Target is a Hong Kong-based company engaged in the development and provision of artificial intelligence-driven financial verification and audit solutions. This strategic acquisition is expected to strengthen Advanced Biomed’s capabilities in the fast-growing fintech and AI sectors.

Conditions for Closing

• Completion of satisfactory financial and legal due diligence reviews by Advanced Biomed Inc.
• Receipt of any and all regulatory approvals required for the acquisition.

The closing date will be mutually determined by the parties once all conditions are satisfied.

Strategic Rationale and Potential Impact

• Entry into AI Financial Solutions: The acquisition marks Advanced Biomed’s entry into the AI-powered financial verification and audit market, which could be seen as a diversification and growth opportunity. This move positions the company to capitalize on the increasing demand for automated and intelligent financial compliance tools in Asia and potentially beyond.
• Share Issuance and Dilution: The purchase price will be paid in newly issued shares, which may have a dilutive effect on current shareholders. Investors should monitor how this impacts the overall share structure and future earnings per share.
• Regulatory Approvals: The deal is not final until all due diligence and regulatory requirements are met. Any delays or failure to secure approvals could impact the anticipated benefits of the acquisition.
• Emerging Growth Company Status: As an emerging growth company, Advanced Biomed may benefit from certain reduced reporting requirements, but it has not opted out of the extended transition period for new accounting standards.
• Potential Share Price Movement: The market may view this acquisition positively, given the expansion into AI and fintech. However, the effect will depend on the perceived synergies, integration success, and actual performance of the acquired business.

Additional Information

The full text of the Share Purchase Agreement is available as an exhibit to the company’s Form 8-K. Investors are encouraged to review this document for further details.

The report was signed by Mr. Yi Lu, Chief Executive Officer of Advanced Biomed Inc., on April 3, 2026.

Conclusion

This acquisition is a significant step for Advanced Biomed Inc. as it seeks to expand its footprint in the AI and financial technology sectors. Shareholders should closely monitor subsequent filings for updates on the completion of due diligence, regulatory approvals, and the anticipated closing of the transaction.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult their financial advisors before making investment decisions. The information herein is based on filings and other publicly available sources believed to be reliable as of the date of this article, but no representation or warranty is made as to its accuracy or completeness. Advanced Biomed Inc. may make further filings or announcements that could affect the information contained in this article.

View Advanced Biomed Inc. Historical chart here